L-carnitine and cognitive function

Wang, S. Fumction Conceptualization, data curation, Fat burner for toning, L-cwrnitine draft. If you found this evidence helpful, please consider donating cognitivw Cochrane. If you need to make more complex queries, use the tips below to guide you. Of the different forms, acetyl-L-carnitine and L-carnitine are the most popular and seem to be the most effective. bottom of page.

L-carnitine and cognitive function -
For patients with less severe cognitive problems, specifically mild cognitive impairment or early-stage Alzheimer's disease, the clinical trial evidence is slightly more positive but also less reliable [11].

Some side effects noted in clinical trials include diarrhea, nausea, and vomiting [1]. Carnitine can inhibit thyroid hormone activity, so those seeking treatment for hypothyroidism should not take any form of carnitine supplement [12]. In addition, some research suggests that certain gut bacteria can convert carnitine to a substance called trimethylamine-N-oxide TMAO , which may be associated with an increased risk of cardiovascular disease.

However, this not well understood and needs more research [13]. NOTE: This is not a comprehensive safety evaluation or complete list of potentially harmful drug interactions. It is important to discuss safety issues with your physician before taking any new supplement or medication.

ALCAR is a common, over-the-counter supplement. There are many natural sources of carnitine, such as red meat, fish, poultry, and some dairy products, but obtaining the doses used in previous clinical trials requires taking a dietary supplement.

For more information, visit the NIH's health information fact sheet. More information on carnitine supplementation can be found at Drugs. Potential Benefit. APOE4 Carriers: Little evidence exists on how carnitine treatment affects APOE4 positive or negative patients.

For Dementia Patients Despite some promise from early clinical trials, a meta-analysis of clinical trials concluded that ALCAR supplements are unlikely to provide a clinically meaningful benefit on the cognitive, behavioral, or functional abilities of Alzheimer's patients [1].

Hudson S, Tabet N Acetyl-L-carnitine for dementia. The Cochrane database of systematic reviews , CD Jones LL, McDonald DA, Borum PR Acylcarnitines: role in brain. Progress in lipid research 49, Malaguarnera M, Cammalleri L, Gargante MP et al. The American journal of clinical nutrition 86, Malaguarnera M, Gargante MP, Cristaldi E et al.

Archives of gerontology and geriatrics 46, Lodeiro M, Ibanez C, Cifuentes A et al. Journal of Alzheimer's disease : JAD 41, Cristofano A, Sapere N, La Marca G et al.

PloS one 11, e Hagen TM, Ingersoll RT, Wehr CM et al. Conclusion : These findings suggest that regular follow-up of serum carnitine levels and replacement of LC could be positive factors in improving cognitive function in patients on HD.

Cite this article as : Atılgan KG, Yalçındağ A, Örsel S, Aylı MD. Could L-Carnitine Treatment Have a Protective Role in the Cognitive Function of Patients Undergoing Hemodialysis?. Turk J Nephrol ; 30 1 : MOST CITED ARTICLES.

Kidney Health for Everyone Everywhere - from Prevention to Detection and Equitable Access to Care Li et al. Acute Kidney Injury in SARS-CoV-2 Infected Critically III Patients Gündoğan et al. Proteolytic Activation of the Epithelial Sodium Channel in Nephrotic Syndrome by Proteasuria: Concept and Therapeutic Potential Artunc, Ferruh.

Clinical Features and Outcomes of Patients with Granulomatosis with Polyangiitis and Review of Literature Arslan et al. Coronavirus Disease Infection and Nursing in Patients Undergoing Hemodialysis Treatment Demirağ and Hintistan.

Serum Total Sialic Acid and Lipid-linked Sialic Acid May Be the New Potential Biomarkers in Paracetamol Nephrotoxicity Öksüz et al. Prevalence and Characteristics of Atrial Fibrillation in Turkish Patients Undergoing Hemodialysis Hasbal et al.

The Turkish Society of Nephrology from to A Year History Kenan Ateş. Evaluation of Long-Term Thirst due to Ramadan Fasting in Terms of Acute Kidney Injury Baloğlu et al. Examination of the Effects of Nursing Interventions on Intradialytic Hypotension Kesik and Özdemir. POPULAR ARTICLES. Burden, Access, and Disparities in Kidney Disease Crews et al.

A New Beginning with a New Name Bülent Tokgöz. Home Could L-Carnitine Treatment Ha Original Article. Could L-Carnitine Treatment Have a Protective Role in the Cognitive Function of Patients Undergoing Hemodialysis?

Searching for just Hypertension and hormonal imbalances few fuunction should be enough to get started. If you need Fat burner for toning make more complex queries, use the L-carnitinw Fat burner for toning to guide you. Shibboleth log in. IOS Press, Inc. For editorial issues, like the status of your submitted paper or proposals, write to [email protected]. IOS Press Nieuwe Hemweg 6B BG Amsterdam The Netherlands. For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected].

L-carnitine and cognitive function -
ALCAR is a common, over-the-counter supplement. There are many natural sources of carnitine, such as red meat, fish, poultry, and some dairy products, but obtaining the doses used in previous clinical trials requires taking a dietary supplement. For more information, visit the NIH's health information fact sheet.

More information on carnitine supplementation can be found at Drugs. Potential Benefit. APOE4 Carriers: Little evidence exists on how carnitine treatment affects APOE4 positive or negative patients. For Dementia Patients Despite some promise from early clinical trials, a meta-analysis of clinical trials concluded that ALCAR supplements are unlikely to provide a clinically meaningful benefit on the cognitive, behavioral, or functional abilities of Alzheimer's patients [1].

Hudson S, Tabet N Acetyl-L-carnitine for dementia. The Cochrane database of systematic reviews , CD Jones LL, McDonald DA, Borum PR Acylcarnitines: role in brain.

Progress in lipid research 49, Malaguarnera M, Cammalleri L, Gargante MP et al. The American journal of clinical nutrition 86, Malaguarnera M, Gargante MP, Cristaldi E et al. Archives of gerontology and geriatrics 46, Lodeiro M, Ibanez C, Cifuentes A et al. Journal of Alzheimer's disease : JAD 41, Cristofano A, Sapere N, La Marca G et al.

Well-designed, randomised, placebo-controlled trials of L-carnitine for cognition enhancement in cognitively healthy people, with large samples and relatively long-term follow-up, are still needed.

Safe interventions to enhance cognitive function in cognitively healthy people would be very valuable for several reasons , including a better quality of life and professional success. While L-carnitine has been reported to enhance cognitive function in some conditions, its efficacy is disputed.

The evidence of its efficacy for cognitively healthy people has not previously been systematically reviewed. To assess the efficacy and safety of L-carnitine for the enhancement of cognitive function in people without cognitive impairment.

We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group's Specialized Register, on 4 November We used the search terms 'L-carnitine' or 'acetyl-L-carnitine' or 'propionyl-L-carnitine' or 'ALC' or 'PLC' or 'ALCAR' or 'ALPAR'.

We ran additional separate searches in several other sources to ensure that we retrieved the most up-to-date results. We also reviewed the bibliographies of the randomised controlled trials identified and contacted the authors and known experts in the field and pharmaceutical companies to identify additional published or unpublished data.

Eligible trials were randomised controlled trials RCTs or quasi-RCTs, parallel-group or cross-over, that compared L-carnitine or its derivatives, acetyl-L-carnitine or propionyl-L-carnitine, at any dose and for any length of treatment, with placebo or no treatment in cognitively healthy people of any age and either gender.

We used standard methodological procedures expected by Cochrane. Two review authors independently selected trials and evaluated the methodological quality, then extracted and analysed data from the included trials. Only two RCTs were eligible. One was a cross-over trial with 18 participants.

The other randomised participants to one of four treatments, of which two L-carnitine and placebo were relevant to this review, but the exact numbers of participants in these two treatment groups was not reported.

All participants were young adults. Methodological details were poorly reported, and we considered the risk of bias in both studies to be unclear. The trials assessed different cognitive outcomes. We could extract cognitive data on approximately participants from one trial.

We found no evidence that L-carnitine has any effect on reaction time, vigilance, immediate memory, or delayed recall after three days of treatment.

Dig Dis Sci — Malaguarnera M, Cammalleri L, Gargante MP, Vacante M, Colonna V, Motta M L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial.

Am J Clin Nutr 86 6 — Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.

Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G a Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy.

Scand J Gastroenterol 46 6 — Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, Galvano F b Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 93 4 — Matsuoka M, Igisu H Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia.

Biochem Pharmacol — Montgomery SA, Thal LJ, Amrein R Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.

Int Clin Psychopharmacol — Neary JT, Norenberg LO, Gutierrez MP, Norenberg MD Hyperammonemia causes altered protein phosphorylation in astrocytes. Brain Res — Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, Benatti P, Calvani M Carnitine: an osmolyte that plays a metabolic role.

J Cell Biochem — Mol Psychiatry — Poveda MJ, Bernabeu A, Concepción L, Roa E, de Madaria E, Zapater P, Pérez-Mateo M, Jover R Brain edema dynamics in patients with overt hepatic encephalopathy A magnetic resonance imaging study. NeuroImage — Pugh RN, Murray-Lyon IM, Dawson JL, Petroni MC, Williams R Transection of the oesophagus for bleeding oesophageal varices.

Br J Surg — Qureshi K, Rao KV, Qureshi IA Differential inhibition by hyperammonemia of the electron transport chain enzymes in synaptosomes and non-synaptic mitochondria in ornithine transcarbamylase-deficient spf-mice: restoration by acetyl-L-carnitine.

Rao KV, Mawal YR, Qureshi IA Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion. Neurosci Lett — Ratnakumari L, Qureshi IA, Butterworth RF Effect of L-carnitine on cerebral and hepatic energy metabolites in congenitally hyperammonemic sparse-fur mice and its role during benzoate therapy.

Metabolism — Reitan RM, Wolfson D The Halstead-Reitan: neuropsychological test battery: theory and clinical interpretation. Neuropsychology Press, Tucson. Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M et al Long-term acetyl-L-carnitine treatment in Alzheimer's disease.

Neurology — Sunderland A, Harris JE, Baddeley AD Do laboratory tests predict A neuropsychological study. J Verbal Learning Verbal Behav — Thal LJ, Calvani M, Amato A, Carta A A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Van Der Rijt C, Schalm SW Quantitative EEG analysis and survival in liver disease.

Electroencephalogr Clin Neurophysiol — Virmani A, Binienda Z Role of carnitine esters in brain neuropathology. Mol Aspects Med — Voigt M, Conn H Hepatic encephalopathy. In: Robson SC, Trey C, Kirsch RE eds Diagnosis and management of liver disease. Wechsler D A standardized Memory Scale for Clinical use.

J Psychol World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects. Wright G, Jalan R Ammonia and inflammation in the pathogenesis of hepatic encephalopathy: Pandora's box?

Download references. Department of Neurosciences, University of Catania, Catania, Italy. Department of Infectious Diseases, University of Catania, Catania, Italy. You can also search for this author in PubMed Google Scholar.

Correspondence to Michele Malaguarnera. Reprints and permissions. Malaguarnera, M.

The aim of cgnitive study was to investigate Enzymes for digestive disorders Weight gain inspiration of ALC treatment on L--carnitine Fat burner for toning in patients L-carnitin severe hepatic encephalopathy. This was a randomized, double-blind, placebo-controlled study. Clinical and laboratory assessment, psychometric tests and automated electroencephalogram EEG analysis were performed for all patients. The improvement of cognitive deficits, the reduction of ammonia, and the modification of EEG in patients treated with ALC suggest that ALC could represent a new tool in the treatment of severe hepatic encephalopathy. This is a preview of subscription content, log in via an institution to check access. Rent this article via DeepDyve. Institutional subscriptions.